(NewsDirect)
By Julian Richard, Benzinga
Metabolism is thechemical process whereby the body produces energy from food. By breaking downcarbohydrates and fats into sugars, the cells access fuel that can beused or stored via the liver or body fat. A metabolic disorder canoccur when the body's chemical reactions become abnormal. Thisresults in metabolic syndrome, where there is an excess or scarcity ofhealth-preserving essential substances. Metabolicsyndrome includes diseases such as obesity (increased fatdeposits in the body) and increased glucose in the blood. Theseconditions increase the risk of comorbidities, such as obesity, type 2diabetes, heart disease, and stroke.
Obesity has become a global epidemic .For example, upto 40% of adults in the USA are obese, and the rates continueto climb across multiple populations. By 2030, overone billion individuals worldwide are predicted to be obese,with 1 in 7 men and 1 in 5 women living with the condition. Obesity isassociated with an increased incidence of type 2 diabetes, heartdisease, stroke, arthritis, sleep apnea, and some cancers. Obesity isestimated to increaseU.S. healthcare spending by $170 billion annually, so it is nosurprise that companies like Novo Nordisk (NYSE: NVO), Pfizer (NYSE: PFE), Eli Lilly (NYSE: LLY) and Teva (NYSE: TEVA) are working on the epidemic as well.
The Centers for Disease Control andPrevention (CDC) reported that in 2022 over 37million Americans had diabetes, with up to 95% having type 2diabetes. Type 2 diabetes has been considered a disease inadults . However, it is becoming more common in children,adolescents and younger adults.
Stem Cells - Harnessing TheMost Potent Cell In The Body
BioRestorative Therapies Inc (NASDAQ:BRTX) focuses on innovative “home-grown” solutions to treatmetabolic syndrome. It was founded by medical doctors, scientists, andworld-renowned stem-cell researchers committed to developing stem-celltherapies to address unmet needs in patients with common yet seriousdiseases.
Pioneeringresearch led by Biorestorative Therapies on newly identifiedhuman adult brown fat stem cells has led to the development ofThermoStem®, a possibly revolutionary “off the shelf” allogeneiccell-based therapeutic.
Stem cells are a unique kind of therapeutic cell. They are someof the most potent cells in the body, which can develop into manyother more specialized and organ or tissue-specific cells. Brown fatstem cells are taken from a healthy donor and grown in the laboratorybefore being transplanted into the patient's body to generate newbrown fat tissue or initiate metabolic homeostasis. Brown fat regulatesbody temperature by breaking down body fat and glucose in theblood. Brown fat produces energy and in so doing burns calories.Individuals with detectable brown fat are at a reducedrisk of being diagnosed with cardiovascular and metabolicissues, such as type 2 diabetes, congestive heart failure, and highblood pressure.
The ThermoStem® program harnesses the body’s ability tocreate new brown fat tissue from human brown adipose-derived stemcells. The novelty of the technology was acknowledged by the EuropeanPatent Office’s Noticeof Allowance issued on the 6th of February, 2023.
A bright future couldawait BioRestorative Therapies and the metabolic syndrome market ingeneral. This is due to the heightened demand for personalizedonce-off treatments for the increasing number of individuals withlifestyle diseases and metabolic syndrome. There is also some intenseclinical interest in this space.
In 2017, the global metabolic disordertherapeutics market was valued at $49.65billion and was projected to experience an impressive CAGR of7.56% from 2019 to 2025. North America is the leading region drivingthis growth. The increasing prevalence of obesity and diabetes, highhealthcare spending, and rising awareness about metabolic disorderscontinue to propel regional market growth even further.
The Asia-Pacific regionis anticipated to experience the most rapid CAGR of 8.27% due to itsfast-paced economic growth. The APAC market is driven by shiftinglifestyles and greater disposable income levels, leading to increasedobesity and diabetes.
Visit https://www.biorestorative.com for more information on the company and its product candidates.
This article wasoriginally published on Benzinga here .
BioRestorativeTherapies was founded by scientists and researchers committed todeveloping stem cell therapies to address unmet needs in patients withhighly prevalent conditions.Our advances in stem cell biology anddelivery protocols harbor great promise in conditioning our bodies’own regenerative potential to treat major diseases more effectivelythan current interventions.Today, BioRestorative is activelydeveloping programs that aim to dramatically increase quality of carefor both (i) chronic back pain caused by disc degeneration, as well as(ii) metabolic disorders including obesity anddiabetes.
This post contains sponsored advertisingcontent. This content is for informational purposes only and is notintended to be investing advice.
ContactDetails
Investor Relations
CompanyWebsite
https://www.biorestorative.com/
Copyright (c) 2023 TheNewswire - All rights reserved.